| Variable . | PM . | No PM . | Total . | P value . |
|---|---|---|---|---|
| n = 29 (15.7%) . | n = 156 (84.3%) . | n = 185 . | ||
| Baseline characteristics | ||||
| Age | 81.5 ± 7 | 80.1 ± 7.3 | 80.4 ± 7.2 | 0.32 |
| Gender, female (n, %) | 11 (37.9%) | 70 (44.9%) | 81 (43.8%) | 0.48 |
| BMI (kg/m2) | 25 ± 5.7 | 27 ± 4.8 | 26.7 ± 5 | 0.03 |
| NYHA—before TAVI | 2.6 ± 0.5 | 2.4 ± 0.6 | 2.5 ± 0.6 | 0.23 |
| DM (n, %) | 3 (10%) | 32 (21%) | 35 (19%) | 0.19 |
| HT (n, %) | 16 (55%) | 108 (70%) | 124 (67%) | 0.12 |
| CAD (n, %) | 10 (34.5%) | 70 (45.2%) | 80 (43.2%) | 0.16 |
| CKF (n, %) | 7 (24.1%) | 22(14.2%) | 29(15.7%) | 0.17 |
| Medications—before TAVI | ||||
| ASA (n, %) | 16 (56%) | 86 (55%) | 102 (55.1%) | 0.94 |
| OAC (n, %) | 12 (41.4%) | 55 (35.5%) | 67 (36.4%) | 0.53 |
| Beta-blocker (n, %) | 11 (38%) | 68 (44.2%) | 79 (43.2%) | 0.53 |
| ACEI (n, %) | 6 (21.4%) | 28 (18%) | 34 (18.6%) | 0.67 |
| ARB (n, %) | 12 (41.4%) | 61 (39%) | 74 (39.5%) | 0.81 |
| CCB (n, %) | 8 (27.6%) | 41(26.5%) | 49 (26.6%) | 0.89 |
| Variable . | PM . | No PM . | Total . | P value . |
|---|---|---|---|---|
| n = 29 (15.7%) . | n = 156 (84.3%) . | n = 185 . | ||
| Baseline characteristics | ||||
| Age | 81.5 ± 7 | 80.1 ± 7.3 | 80.4 ± 7.2 | 0.32 |
| Gender, female (n, %) | 11 (37.9%) | 70 (44.9%) | 81 (43.8%) | 0.48 |
| BMI (kg/m2) | 25 ± 5.7 | 27 ± 4.8 | 26.7 ± 5 | 0.03 |
| NYHA—before TAVI | 2.6 ± 0.5 | 2.4 ± 0.6 | 2.5 ± 0.6 | 0.23 |
| DM (n, %) | 3 (10%) | 32 (21%) | 35 (19%) | 0.19 |
| HT (n, %) | 16 (55%) | 108 (70%) | 124 (67%) | 0.12 |
| CAD (n, %) | 10 (34.5%) | 70 (45.2%) | 80 (43.2%) | 0.16 |
| CKF (n, %) | 7 (24.1%) | 22(14.2%) | 29(15.7%) | 0.17 |
| Medications—before TAVI | ||||
| ASA (n, %) | 16 (56%) | 86 (55%) | 102 (55.1%) | 0.94 |
| OAC (n, %) | 12 (41.4%) | 55 (35.5%) | 67 (36.4%) | 0.53 |
| Beta-blocker (n, %) | 11 (38%) | 68 (44.2%) | 79 (43.2%) | 0.53 |
| ACEI (n, %) | 6 (21.4%) | 28 (18%) | 34 (18.6%) | 0.67 |
| ARB (n, %) | 12 (41.4%) | 61 (39%) | 74 (39.5%) | 0.81 |
| CCB (n, %) | 8 (27.6%) | 41(26.5%) | 49 (26.6%) | 0.89 |
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CKF, chronic kidney failure; DM, diabetes mellitus; HT, hypertension; OAC, oral anticoagulant; NYHA, New York Heart Association; OSAS, obstructive sleep apnoea syndrome.
| Variable . | PM . | No PM . | Total . | P value . |
|---|---|---|---|---|
| n = 29 (15.7%) . | n = 156 (84.3%) . | n = 185 . | ||
| Baseline characteristics | ||||
| Age | 81.5 ± 7 | 80.1 ± 7.3 | 80.4 ± 7.2 | 0.32 |
| Gender, female (n, %) | 11 (37.9%) | 70 (44.9%) | 81 (43.8%) | 0.48 |
| BMI (kg/m2) | 25 ± 5.7 | 27 ± 4.8 | 26.7 ± 5 | 0.03 |
| NYHA—before TAVI | 2.6 ± 0.5 | 2.4 ± 0.6 | 2.5 ± 0.6 | 0.23 |
| DM (n, %) | 3 (10%) | 32 (21%) | 35 (19%) | 0.19 |
| HT (n, %) | 16 (55%) | 108 (70%) | 124 (67%) | 0.12 |
| CAD (n, %) | 10 (34.5%) | 70 (45.2%) | 80 (43.2%) | 0.16 |
| CKF (n, %) | 7 (24.1%) | 22(14.2%) | 29(15.7%) | 0.17 |
| Medications—before TAVI | ||||
| ASA (n, %) | 16 (56%) | 86 (55%) | 102 (55.1%) | 0.94 |
| OAC (n, %) | 12 (41.4%) | 55 (35.5%) | 67 (36.4%) | 0.53 |
| Beta-blocker (n, %) | 11 (38%) | 68 (44.2%) | 79 (43.2%) | 0.53 |
| ACEI (n, %) | 6 (21.4%) | 28 (18%) | 34 (18.6%) | 0.67 |
| ARB (n, %) | 12 (41.4%) | 61 (39%) | 74 (39.5%) | 0.81 |
| CCB (n, %) | 8 (27.6%) | 41(26.5%) | 49 (26.6%) | 0.89 |
| Variable . | PM . | No PM . | Total . | P value . |
|---|---|---|---|---|
| n = 29 (15.7%) . | n = 156 (84.3%) . | n = 185 . | ||
| Baseline characteristics | ||||
| Age | 81.5 ± 7 | 80.1 ± 7.3 | 80.4 ± 7.2 | 0.32 |
| Gender, female (n, %) | 11 (37.9%) | 70 (44.9%) | 81 (43.8%) | 0.48 |
| BMI (kg/m2) | 25 ± 5.7 | 27 ± 4.8 | 26.7 ± 5 | 0.03 |
| NYHA—before TAVI | 2.6 ± 0.5 | 2.4 ± 0.6 | 2.5 ± 0.6 | 0.23 |
| DM (n, %) | 3 (10%) | 32 (21%) | 35 (19%) | 0.19 |
| HT (n, %) | 16 (55%) | 108 (70%) | 124 (67%) | 0.12 |
| CAD (n, %) | 10 (34.5%) | 70 (45.2%) | 80 (43.2%) | 0.16 |
| CKF (n, %) | 7 (24.1%) | 22(14.2%) | 29(15.7%) | 0.17 |
| Medications—before TAVI | ||||
| ASA (n, %) | 16 (56%) | 86 (55%) | 102 (55.1%) | 0.94 |
| OAC (n, %) | 12 (41.4%) | 55 (35.5%) | 67 (36.4%) | 0.53 |
| Beta-blocker (n, %) | 11 (38%) | 68 (44.2%) | 79 (43.2%) | 0.53 |
| ACEI (n, %) | 6 (21.4%) | 28 (18%) | 34 (18.6%) | 0.67 |
| ARB (n, %) | 12 (41.4%) | 61 (39%) | 74 (39.5%) | 0.81 |
| CCB (n, %) | 8 (27.6%) | 41(26.5%) | 49 (26.6%) | 0.89 |
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CKF, chronic kidney failure; DM, diabetes mellitus; HT, hypertension; OAC, oral anticoagulant; NYHA, New York Heart Association; OSAS, obstructive sleep apnoea syndrome.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
